Jeeyun Lee MD
@JeeyunM
Followers
190
Following
360
Media
5
Statuses
63
Oncologist Samsung Medical Center
Republic of Korea
Joined May 2021
With interest in PD-1xVEGF across cancers we add some data from Ram and Pembro. @CIR_AACR @JeeyunM @AnMinae @arnavmehta3 Distinct spatially resolved TME trajectories define benefit from ramucirumab + pembro in refractory PD-L1+ gastric cancer
aacrjournals.org
Abstract. The activity of bispecific antibodies against vascular endothelial growth factor (VEGF) and programmed death ligand-1 (PD-1) have reinvigorated interest in dual VEGF and PD-1 targeting...
2
6
33
Collaboration led by @JeeyunM @jitcancer @sitcancer: After 1 cycle chemo, 4/10 (40%) CLDN18.2+ tumors lost expression and 3/29 (10.3%) gained it. CLDN18.2+ TMEs are immune-inflamed yet fibrotic (TGF-β/ECM+) supports serial testing and combo strategies https://t.co/ITXHeMl3Bq
4
17
76
https://t.co/emgr598wG0 Nice collaboration with @KoheiShitara @AnMinae Takeshi Kuwata on dynamic change of claudin 18.2 during chemo plus pem tx.
jitc.bmj.com
Background Claudin 18.2 (CLDN18.2) is a tight junction protein retained in malignant transformation of gastric cancer (GC) and is a promising therapeutic target. Despite the clinical benefit of...
0
1
3
Stay Connected with #KSMO_INTL at #ASCO25 We're excited to meet Korea–US oncologists at this special networking event!🥂 Let’s connect🤝, collaborate🧩, and celebrate together!🎉 👉Learn more https://t.co/H3pgmi6Vqi
0
4
3
Tremelimumab & durvalumab as neoadjuvant or non-operative management strategy for MSI GC/GEJ cancer @Annals_Oncology
https://t.co/bSzGbM0uPF 🔎 INFINITY study by GONO 👉17 pts > 13 cCR > non-operative management > only 1 recurrence 🧐W&W in GC/GEC ... exciting @myESMO
1
10
34
Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial https://t.co/9Ib0j2ycXq
@JeeyunM @AnMinae @arnavmehta3 @CCR_AACR
1
5
39
Claudin 18.2 and Fgfr2b in GC as first-line tx. Thanks to #weipengyong #hisatokaeakami, Dr. Kyoung Mee Kim #esmo2024 for insightful panel discussions. Exciting time to treat GI cancers with more tx options yet to come. #anminae
0
0
2
🔥#KSMO2024 #JSMO2025 booth 🙌We welcome 🇰🇷 and 🌎🌍participants to Kobe🇯🇵 🗓March 6th to 8th, 225 ✔️English as Official language ✔️Joint symposium with @ASCO, @myESMO and more @KSMO_INTL @JSMO_official
#LCSM @OncoAlert
2
8
39
I’m deeply honored to receive this award (future leader award) for my postdoctoral work. https://t.co/CHP4Lx7sdh
https://t.co/X2O48xTvCH I am also incredibly grateful to my mentor @JeeyunM and my colleagues who guided and worked alongside me.
1
1
2
Thank you for ASCO sessions especially @lynn_schuchter. @ASCO. We see stage iv everyday but still hard to judge when to start palliative care for each patient. @KSMO_INTL
Enjoying Day 2 @ KSMO 2024, & today @lynn_schuchter co-chairs ASCO/KSMO Joint Symposium 7 w/ Dr. Kyung Hee Lee & speaks about integrating #palliativecare into onc care along w/ @tomleblancMD, @jungyong_hong. If you’re here at COEX, visit us @ the ASCO Booth in Hall 3F. @KSMO_INTL
1
1
18
@AndresC27622123 discussing neoadjuvant treatment of rectal cancers @KSMO_INTL @myESMO joint session in #Seoul.
0
2
6
I'm excited to see this early data at #ESMO24 on AMG 193 for my patients with pancreas, biliary & oesophageal cancer 👏👏 MTAP deletion is a new target for hard to treat cancers https://t.co/U8d647FL2E
#Presidential @myESMO
3
24
91
Niche 2 after two doses of nivolumab and one dose of ipi and surgery. 100% of patients with MSI high colon cancer relapse free at 3 years. Arguably preop IO should be a new care standard in MSI high colon cancer.
3
20
62
Extremely fortunate 💜to have the best mentor @EileenMOReilly and mentee @CatherineaOC A strong teamwork at @MSKCancerCenter We are sharing each other's slides in transatlantic presentations at #AACRpan24 and #ESMO24 A lot of active research👨🔬@CpcrMsk Congrats! Keynote 📢speech
1
16
63
Pembrolizumab + CAPOX /bevacizumab in MSS CRC and a high immune infiltrate #ESMO24 🔎POCHI trial 👉ORR 74%, DRC 100%, 5 CR 👉12-mo PFS rate 51% 👉2-yr OS rate 80% 👉AEs ≥3 70% 🧐IMMUNOSCORE and TuLIS score (18% of pts) to select ICI in mCRC? @myESMO #ESMOAmbassadors
0
50
99
Pleased to share final survival results of two phase 3 of zolbetuximab @NEJM which reinforce zolbetuxumab plus chemo as effective treatment option, though still need better treatment. More agents will be coming for CLDN18.2+ GC @myESMO @OncoAlert #ESMO24
nejm.org
The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemoth...
Presented at #ESMO24: The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemotherapy alone. Full correspondence: https://t.co/szFvJel6JC
4
61
158
#ESMO24 T-DXd monotherapy and combinations in pts with advanced HER2+ esophageal, gastric or GEJ adenocarcinoma: DESTINY-Gastric03 Toxicity is high at 6.4 mg, while the follow-up period for 5.4 mg is quite short. The 5.4 mg dose shows promise. Longer follow-up is needed
0
8
22
🌟Join us at KSMO Annual Meeting🌟 Stay connected with Korean oncologists at COEX, Seoul, Korea & online on September 26-27! Highlights include annual joint sessions of @ASCO @myESMO @JSMO_official Register now!👉 https://t.co/gy3cOwAThd
0
4
17